Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112 is registered in ClinicalTrials.gov with Diakonos Oncology Corporation as lead sponsor.

NCT NCT07288112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07288112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Lead sponsor
Diakonos Oncology Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 6, 2026
Completion date
January 31, 2033
Enrollment
35 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

refractory melanoma